Plaque Psoriasis

Jerry Bagel, MD, MS, discusses the relationship between a physician and physician assistant treating plaque psoriasis.

Among flares identified in outpatient (53%), inpatient (36%), and emergency department (9%) settings, the most utilized treatments were topical corticosteroids (35%), opioids (21%), and other oral treatments.

Experts in plaque psoriasis discuss how patients are referred to them for treatment.

Jerry Bagel, MD, MS, and Alexa Hetzel, MS, PA-C, touch on unmet needs that remain in the treatment of plaque psoriasis.

Dr Jerry Bagel and physician assistant Alexa Hetzel comment on other agents available for the treatment of plaque psoriasis.

Jerry Bagel, MD, MS, and Alexa Hetzel, MS, PA-C, discuss the safety and efficacy of deucravacitinib in patients with plaque psoriasis.

The pivotal DERMIS trial author discusses extended assessment and prescribing strategies for the latest psoriasis agent.

A retrospective analysis suggests there are significant disparities in dermatologist visit duration based on patient race and ethnicity.

Dermatologist Raj Chovatiya, MD, PhD, discusses practical use of the newest topical therapy approved by the FDA.

The indication to Arcutis makes the once-daily topical cream the first marketed PDE4 inhibitor of its kind.

Panelists talk about when they might consider switching biologics for patients with plaque psoriasis.

Experts in plaque psoriasis discuss how to select a biologic based on patient factors and comorbidities.

Jerry Bagel, MD, MS, and Alexa Hetzel, MS, PA-C, discuss their experiences with biologics used to treat plaque psoriasis.

Jerry Bagel, MD, MS, discusses the mechanism of action of biologics used in plaque psoriasis.

In the study, 77% of patients treated with the Cal/BD foam treatment were satisfied with its effectiveness, 60% were satisfied with its ease of use, and 73.9% were satisfied in terms of global satisfaction.

Dr. Jerry Bagel and physician assistant, Alexa Hetzel, comment on the burden of plaque psoriasis and what options are available for the treatment of plaque psoriasis.

Jerry Bagel, M.D., M.S. and Alexa Hetzel, M.S., PA-C discuss an overview of plaque psoriasis and how plaque psoriasis impacts quality of life.

An analysis of PSOARING 1 and 2 data show the topical therapy is efficacious across a wide spectrum of psoriatic disease and patient demographics.

An analysis suggests patients on the biologic fared better with adherence and outcomes than those on competitors including adalimumab.

New phase 3 extension data show the topical PDE-4 inhibitor provided skin clearance to a significant rate of patients with psoriasis.

Promising 2-year data for the IL-17 targeting biologic were recently presented at AAD 2022.

Exact triggers in acute urticaria and chronic urticaria are largely unknown, with the success of identifying causes of AU varying between 21-68%.

Previous research has suggested that psoriasis could affect both fecundity and fertility, leading to spontaneous abortion and ectopic pregnancy.

The current registered dosing of the therapy is 30 mg twice daily, but the analyzed dosage of 20 mg has not yet been approved.

Similarly, patients affected by alopecia areata had higher odds of developing psoriasis.